1. Home
  2. IOVA vs NIE Comparison

IOVA vs NIE Comparison

Compare IOVA & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.60

Market Cap

881.3M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$25.48

Market Cap

705.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
NIE
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
881.3M
705.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IOVA
NIE
Price
$2.60
$25.48
Analyst Decision
Buy
Analyst Count
12
0
Target Price
$10.45
N/A
AVG Volume (30 Days)
12.8M
70.5K
Earning Date
02-26-2026
01-01-0001
Dividend Yield
N/A
9.04%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$250,425,000.00
N/A
Revenue This Year
$60.71
N/A
Revenue Next Year
$59.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
175.62
N/A
52 Week Low
$1.64
$18.61
52 Week High
$6.36
$22.47

Technical Indicators

Market Signals
Indicator
IOVA
NIE
Relative Strength Index (RSI) 51.15 52.18
Support Level $2.21 $25.20
Resistance Level $3.03 $25.71
Average True Range (ATR) 0.20 0.29
MACD 0.00 -0.01
Stochastic Oscillator 48.78 60.32

Price Performance

Historical Comparison
IOVA
NIE

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

Share on Social Networks: